Methods and compositions for modulating ACE-2 activity
    1.
    发明授权
    Methods and compositions for modulating ACE-2 activity 有权
    调节ACE-2活性的方法和组合物

    公开(公告)号:US06900033B2

    公开(公告)日:2005-05-31

    申请号:US10158825

    申请日:2002-06-03

    摘要: Binding polypeptides comprising specific amino acid sequences are disclosed that specifically bind ACE-2 protein or ACE-2-like polypeptides. The binding polypeptides can be used in methods of the invention for detecting, isolating, or purifying ACE-2 protein or ACE-2-like polypeptides in solutions or mixtures, or biological samples. The invention also relates to nucleic acid molecules encoding these ACE-2 binding polypeptides, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention also relates to methods and compositions for detecting, diagnosing, prognosing, preventing, treating or ameliorating a disease or disorder associated with aberrant ACE-2 or ACE-2 receptor expression or inappropriate function of ACE-2 or ACE-2 receptor, comprising use of ACE-2 binding polypeptides or fragments or variants thereof, that specifically bind to ACE-2.

    摘要翻译: 公开了包含特异性氨基酸序列的结合多肽,其特异性结合ACE-2蛋白或ACE-2样多肽。 结合多肽可用于本发明的方法中用于在溶液或混合物或生物样品中检测,分离或纯化ACE-2蛋白或ACE-2样多肽。 本发明还涉及编码这些ACE-2结合多肽的核酸分子,含有这些核酸的载体和宿主细胞及其制备方法。 本发明还涉及用于检测,诊断,预后,预防,治疗或改善与异常ACE-2或ACE-2受体表达或ACE-2或ACE-2受体的不适当功能相关的疾病或病症的方法和组合物, 包括使用特异性结合ACE-2的ACE-2结合多肽或其片段或变体。

    Methods and compositions for modulating ACE-2 activity
    2.
    发明授权
    Methods and compositions for modulating ACE-2 activity 失效
    调节ACE-2活性的方法和组合物

    公开(公告)号:US06592865B2

    公开(公告)日:2003-07-15

    申请号:US10158847

    申请日:2002-06-03

    IPC分类号: A61K3800

    摘要: The invention relates to the use of angiotensin II in combination with angiotesin 1-9 to potentiate angiotensin II activity. The invention also relates to the use of combinations of angiotensin II and angiotensin 1-9 to increase vasoconstriction and to treat disorders associated with low blood pressure.

    摘要翻译: 本发明涉及使用血管紧张素II与血管紧张素I9组合以增强血管紧张素II活性。 本发明还涉及使用血管紧张素II和血管紧张素1-9的组合来增加血管收缩和治疗与低血压相关的疾病。

    Methods and compositions for modulating responsiveness to corticosteroids
    3.
    发明授权
    Methods and compositions for modulating responsiveness to corticosteroids 失效
    调节对皮质类固醇反应的方法和组合物

    公开(公告)号:US6054487A

    公开(公告)日:2000-04-25

    申请号:US820692

    申请日:1997-03-18

    IPC分类号: A61K31/18

    CPC分类号: A61K31/18

    摘要: Method for modulating responsiveness to corticosteroids in a subject are provided. In the method of the invention, an agent which antagonizes a factor that regulates production of IFN-.gamma. in the subject is administered to the subject in combination with a corticosteroid such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject. In one embodiment, the agent is an interferon-.gamma. inducing factor (IGIF) antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunological diseases and disorders. Pharmaceutical compositions comprising an agent which antagonizes a factor that regulates production of IFN-.gamma. in a subject, a corticosteroid and a pharmaceutically acceptable carrier are also provided. A preferred composition comprises an ICE inhibitor, a corticosteroid and a pharmaceutically acceptable carrier.

    摘要翻译: 提供了调节受试者对皮质类固醇的反应性的方法。 在本发明的方法中,将拮抗受试者中IFN-γ产生的因子拮抗的药物与皮质类固醇组合给予受试者,使得受试者对皮质类固醇的反应性与皮质类固醇相比被调节 单独对受试者施用。 在一个实施方案中,所述试剂是干扰素-γ诱导因子(IGIF)拮抗剂。 在另一个实施方案中,该药剂是白细胞介素-12(IL-12)拮抗剂。 在优选的实施方案中,所述试剂是半胱天冬酶家族蛋白酶,优选ICE抑制剂的抑制剂。 在另一个优选的实施方案中,所述试剂是抗IL-12单克隆抗体。 其它优选的试剂包括磷酸二酯酶IV抑制剂和β-2激动剂。 本发明的方法可用于治疗各种炎症和免疫疾病和病症。 还提供了包含拮抗受试者中的IFN-γ生成因子,皮质类固醇和药学上可接受的载体的药剂的药物组合物。 优选的组合物包含ICE抑制剂,皮质类固醇和药学上可接受的载体。